Manufacturer
SANOFI PASTEUR
Contents
Per 0.5 mL Diphtheria toxoid ≥30 IU, tetanus toxoid ≥40 IU, Bordetella pertussis antigens: Toxoid 25 mcg, filamentous haemagglutinin 25 mcg, inactivated poliomyelitis virus (type 1) 40 D antigen units, inactivated poliomyelitis virus (type 2) 8 D antigen units, inactivated poliomyelitis virus (type 3) 32 D antigen units, polysaccharide of HIB 10 mcg conjugated to tetanus protein 18-30 mcg
Indication
Joint prevention of invasive infections caused by HIB, diphtheria, tetanus, pertussis & poliomyelitis: Primary vaccination in infants from 2 mth & as a booster 1 yr after the primary vaccination during the 2nd yr of life.
Instruction
Administer via IM Injection.
Drug interaction
This vaccine can be administered simultaneously with the M-M-RVAXPRO vaccine or with the HBVAXPRO vaccine, but in two separate sites. Interference with laboratory tests: Since the Hib capsular polysaccharide antigen is excreted in the urine, a positive urine test can be observed within 1 to 2 weeks following vaccination. Other tests should be performed in order to confirm Hib infection during this period. Interaction studies were performed in adults only.
Malaysia
